FORM	4
------	---

Check this box if no	
longer subject to	
Section 16. Form 4 or	
Form 5 obligations may	
continue. See	1
T (C 1(1)	

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Instruction 1(b). Company Act of 1940

(Print of Type Responses)											
1. Name and Address of Reporting Person [*] Treco James		2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) C/O TONIX PHARMACEUTICALS HO CORP, 509 MADISON AVENUE, SUI	OLDING 0	3. Date of Earliest Transaction (Month/Day/Year) 05/04/2020						Officer (give title below)Othe	er (specify below	v)	
(Street) NEW YORK, NY 10022	4.	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acqu						uired, Disposed of, or Beneficially Owned			
(Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	3. Transacti Code (Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)			Owned Following Reported Transaction(s) (Instr. 3 and 4)		Beneficial Ownership	
			Code	V	Amount	· ·	Price		(Instr. 4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 Person

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
Security (Instr. 3)	Conversion	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion)		A) d of	6. Date Exercisable and Expiration Date (Month/Day/Year)		xpiration Date of Underlying		Derivative Security (Instr. 5)	Securities Beneficially Owned Following	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	v	(A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares		(msu: 4)	(IIISU: 4)	
Stock Option	\$ 0.77	05/04/2020		А		112,500		05/04/2021 ⁽¹⁾	05/04/2030	Common Stock	112,500	\$ 0 <u>(1)</u>	112,500	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address		10% Owner	Officer	Other				
Treco James C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVENUE, SUITE 1608 NEW YORK, NY 10022	Х							

Signatures

/s/ Jessica Morris, Attorney-in-Fact	05/06/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.